Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.

Russo JJ, Goodman SG, Cantor WJ, Fitchett D, Heffernan M, Borgundvaag B, Ducas J, Cohen EA, Džavik V, Mehta SR, Buller CE, Yan AT; TRANSFER-AMI investigators.

Heart. 2014 Jun;100(11):873-80. doi: 10.1136/heartjnl-2013-305231. Epub 2014 Jan 21.

PMID:
24449716
2.

Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI).

Russo JJ, Goodman SG, Cantor WJ, Tan MK, Borgundvaag B, Fitchett D, Džavík V, Yan RT, Graham JJ, Mehta SR, Yan AT; TRANSFER-AMI Investigators.

Am J Cardiol. 2015 Apr 15;115(8):1005-12. doi: 10.1016/j.amjcard.2015.01.533. Epub 2015 Jan 31.

PMID:
25711435
3.

Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.

Dobrzycki S, Mezyński G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachórzewska-Gajewska H, Sawicki Z, Poniatowski B, Korecki J, Musiał WJ.

Kardiol Pol. 2006 Aug;64(8):793-9; discussion 800-1.

4.

Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).

Bhan V, Cantor WJ, Yan RT, Mehta SR, Morrison LJ, Heffernan M, Fitchett D, Džavík V, Ducas J, Borgundvaag B, Cohen EA, Goodman SG, Yan AT.

Am Heart J. 2012 Sep;164(3):343-50. doi: 10.1016/j.ahj.2012.05.022. Epub 2012 Aug 17.

PMID:
22980300
5.

Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).

Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG; TRANSFER-AMI Investigators.

Eur Heart J. 2011 Aug;32(16):1994-2002. doi: 10.1093/eurheartj/ehr008. Epub 2011 Feb 8.

PMID:
21307037
6.

Efficacy of an early invasive strategy after fibrinolysis in ST-elevation myocardial infarction relative to the extent of coronary artery disease.

Elbarouni B, Cantor WJ, Ducas J, Borgundvaag B, Džavík V, Heffernan M, Buller CE, Langer A, Goodman SG, Yan AT; TRANSFER-AMI Trial Investigators.

Can J Cardiol. 2014 Dec;30(12):1555-61. doi: 10.1016/j.cjca.2014.09.001. Epub 2014 Sep 4.

PMID:
25475460
7.

Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.

Dobrzycki S, Kralisz P, Nowak K, Prokopczuk P, Kochman W, Korecki J, Poniatowski B, Zuk J, Sitniewska E, Bachorzewska-Gajewska H, Sienkiewicz J, Musial WJ.

Eur Heart J. 2007 Oct;28(20):2438-48. Epub 2007 Sep 20.

PMID:
17884846
8.

Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).

Montalescot G, Van de Werf F, Gulba DC, Avezum A, Brieger D, Kennelly BM, Mazurek T, Spencer F, White K, Gore JM; GRACE Investigators.

Catheter Cardiovasc Interv. 2003 Nov;60(3):360-7.

PMID:
14571488
9.

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).

Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ; National Registry of Myocardial Infarction-4.

Am J Cardiol. 2006 Nov 1;98(9):1125-31. Epub 2006 Aug 31.

PMID:
17056312
10.

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.

N Engl J Med. 2001 Jun 21;344(25):1879-87.

12.

Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction).

Tan NS, Goodman SG, Cantor WJ, Tan MK, Yan RT, Bagnall AJ, Mehta SR, Fitchett D, Strauss BH, Yan AT; TRANSFER-AMI Investigators.

Am J Cardiol. 2014 Oct 1;114(7):955-61. doi: 10.1016/j.amjcard.2014.05.069. Epub 2014 Jul 16.

PMID:
25118119
13.

Routine early angioplasty after fibrinolysis for acute myocardial infarction.

Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, Morrison LJ, Langer A, Dzavik V, Mehta SR, Lazzam C, Schwartz B, Casanova A, Goodman SG; TRANSFER-AMI Trial Investigators.

N Engl J Med. 2009 Jun 25;360(26):2705-18. doi: 10.1056/NEJMoa0808276.

15.
16.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators.

JAMA. 2007 Feb 14;297(6):591-602.

PMID:
17299194
17.

Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis.

Belle L, Fourny M, Reynaud T, Hammer L, Vanzetto G, Labarère J; RENAU-RESURCOR study investigators.

Catheter Cardiovasc Interv. 2011 Sep 1;78(3):376-84. doi: 10.1002/ccd.22825. Epub 2011 Mar 16.

PMID:
21413113
18.

Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.

De Servi S, Mariani M, Vandoni P, Dellavalle A, Politi A, Poletti F, Bonizzoni E, Leoncinie M; Registro Osservazionale Angina Instabile (ROSAI-2) Investigators.

J Cardiovasc Med (Hagerstown). 2006 Mar;7(3):159-65.

PMID:
16645379
20.

Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).

Cantor WJ, Fitchett D, Borgundvaag B, Heffernan M, Cohen EA, Morrison LJ, Ducas J, Langer A, Mehta S, Lazzam C, Schwartz B, Dzavik V, Goodman SG.

Am Heart J. 2008 Jan;155(1):19-25. Epub 2007 Oct 25. Erratum in: Am Heart J. 2008 Feb;155(2):323. Ducas, John [added].

PMID:
18082484

Supplemental Content

Support Center